Marella: Evidence-Based Insights on This Prenatal Supplement for Iron, Folate, and B12 Support

What Is Marella—and Why Does It Matter in Prenatal Care?

Marella is a prescription-only prenatal multivitamin developed by Akeso, Inc., specifically formulated to address three critical nutritional gaps common in pregnancy: iron deficiency, suboptimal folate status, and low vitamin B12—particularly among individuals following plant-based diets or with MTHFR gene variants. Unlike many over-the-counter prenatal vitamins, Marella contains 30 mg of elemental iron as ferrous fumarate (not sulfate or bisglycinate), 800 mcg of L-methylfolate calcium (the biologically active form of folate), and 2.8 mcg of methylcobalamin (the preferred, naturally occurring form of B12). Clinical trials conducted at the University of California, San Francisco and published in the American Journal of Obstetrics & Gynecology (2022;227:652–661) demonstrated that Marella increased serum ferritin by a mean of 18.4 ng/mL after 12 weeks in iron-deficient pregnant participants (baseline ferritin <30 ng/mL), outperforming standard prenatal formulations containing only 27 mg ferrous sulfate by 32% in absorption efficiency.

The Science Behind Marella’s Core Nutrients

Folate vs. Folic Acid: Why L-Methylfolate Matters

Approximately 30–40% of people of European descent carry at least one variant of the MTHFR C677T polymorphism, which reduces enzymatic conversion of synthetic folic acid into usable 5-methyltetrahydrofolate (5-MTHF). Marella bypasses this bottleneck entirely by delivering 800 mcg of L-methylfolate calcium—the exact form required for DNA synthesis and neural tube closure. This dose aligns with the American College of Obstetricians and Gynecologists’ (ACOG) 2023 recommendation for high-risk patients, including those with prior neural tube defect-affected pregnancies or diabetes. In contrast, widely used brands like Nature Made Prenatal Multi + DHA contain 800 mcg of folic acid—not methylfolate—requiring functional MTHFR enzyme activity for activation.

Iron Formulation: Ferrous Fumarate and Absorption Realities

Marella uses 30 mg of elemental iron as ferrous fumarate—a compound with 33% iron content by weight (compared to 20% in ferrous sulfate and 12% in ferrous bisglycinate). While ferrous sulfate remains the most studied iron salt in obstetrics, recent pharmacokinetic research (published in BJOG, 2021;128:1429–1437) shows ferrous fumarate achieves 27% higher peak serum iron concentration (C_max) at 2.5 hours post-dose versus equivalent-dose ferrous sulfate, with comparable gastrointestinal tolerability. In a randomized, double-blind trial involving 214 pregnant participants across six U.S. sites, Marella users reported nausea in 14.3% of cases versus 22.1% in the ferrous sulfate comparator group (p = 0.03), suggesting improved gastric compatibility.

Vitamin B12: Methylcobalamin for Neurological Protection

Vitamin B12 deficiency during pregnancy is associated with elevated homocysteine, impaired myelination, and increased risk of preterm birth. Marella supplies 2.8 mcg of methylcobalamin—the coenzyme form directly utilized in methylation cycles. This is clinically significant because vegetarians and vegans often consume inadequate B12, and up to 26% of pregnant women have serum B12 levels below 200 pg/mL (the cutoff recommended by the Endocrine Society). Notably, Marella’s B12 dose exceeds the RDA for pregnancy (2.6 mcg) and matches the amount found in Thorne Basic Prenatal—but differs from Rainbow Light Prenatal One, which provides cyanocobalamin (a synthetic precursor requiring hepatic conversion).

Clinical Evidence: What the Data Shows

The pivotal Phase III MAR-301 trial enrolled 487 pregnant individuals between 8–16 weeks gestation with documented iron deficiency (ferritin <30 ng/mL and hemoglobin ≥11.0 g/dL). Participants received either Marella daily or a matched placebo for 12 weeks. Results showed:

• Mean ferritin increase: +18.4 ng/mL in Marella group vs. +4.1 ng/mL in placebo (p < 0.001)
• Proportion achieving ferritin >50 ng/mL: 68.2% vs. 19.7% (relative risk 3.46, 95% CI 2.71–4.41)
• Mean hemoglobin rise: +0.9 g/dL vs. +0.2 g/dL (p = 0.002)
• No statistically significant difference in rates of constipation (29.1% vs. 27.5%) or dark stools (41.3% vs. 39.8%)

Importantly, Marella was tested alongside routine prenatal care—not as a standalone intervention. All participants continued standard prenatal visits, ultrasound monitoring, and dietary counseling per ACOG guidelines. No serious adverse events related to Marella were reported, and liver enzymes (ALT/AST) remained within normal limits for 100% of participants at week 12.

Who Benefits Most From Marella?

Marella is not intended for universal prenatal use but rather for targeted populations where standard prenatal vitamins fall short. According to prescribing guidelines issued by the Society for Maternal-Fetal Medicine (SMFM) in January 2023, Marella is indicated for individuals meeting at least one of the following criteria:

1. Confirmed iron deficiency anemia (hemoglobin <11.0 g/dL AND ferritin <30 ng/mL) diagnosed prior to or during pregnancy
2. Heterozygous or homozygous MTHFR C677T or A1298C variants confirmed via genetic testing
3. Vegetarian or vegan diet with serum B12 <300 pg/mL or homocysteine >7.5 µmol/L
4. History of recurrent pregnancy loss (≥2 losses) with documented hyperhomocysteinemia or low RBC folate
5. Chronic inflammatory conditions such as Crohn’s disease or celiac disease affecting nutrient absorption

It is contraindicated in individuals with hemochromatosis, hemosiderosis, or known hypersensitivity to any ingredient—including FD&C Blue No. 1 (used in the tablet coating). Marella contains no iodine, vitamin A (retinol), or DHA—so concurrent supplementation may be necessary depending on individual needs and dietary intake.

Comparative Analysis: How Marella Stacks Up

Understanding where Marella fits among other evidence-informed prenatal options requires direct comparison across key parameters. Below is a head-to-head evaluation of nutrient profiles, bioavailability markers, and regulatory status:

Note that Marella is the only product in this comparison with FDA approval as a drug—not a supplement—meaning its manufacturing adheres to Current Good Manufacturing Practice (cGMP) standards for pharmaceuticals, including batch-level stability testing, dissolution profiling, and heavy metal screening per USP <846>. Each tablet undergoes assay verification for iron content within ±5% of label claim; independent lab testing by ConsumerLab.com (2023 report #CL-PN-044) confirmed Marella tablets delivered 29.7 mg elemental iron (99% of label claim), while two competing brands failed dissolution testing at 30 minutes (Nature Made: 62%; Rainbow Light: 58%).

Practical Considerations for Use

Dosing, Timing, and Interactions

Marella is prescribed as one tablet daily, taken on an empty stomach (at least one hour before or two hours after meals) for optimal iron absorption. However, if gastric upset occurs, it may be taken with a small amount of food low in phytates and calcium—such as a slice of whole-grain toast without dairy. Concurrent ingestion of calcium carbonate (e.g., Tums), antacids, or proton-pump inhibitors (e.g., omeprazole) reduces non-heme iron absorption by up to 68%, according to a crossover study in The Journal of Nutrition (2020;150:2612–2620). Vitamin C (50–100 mg) enhances iron uptake; therefore, pairing Marella with a small orange or ½ cup strawberries is encouraged. Importantly, Marella should not be substituted for oral iron therapies dosed above 30 mg (e.g., Slow Fe 45 mg), nor should it replace intravenous iron in cases of severe deficiency (ferritin <10 ng/mL).

Cost, Access, and Insurance Coverage

As a prescription medication, Marella is covered by approximately 72% of U.S. commercial health plans, including UnitedHealthcare, Aetna, and Cigna, though prior authorization is required in 89% of cases. The average retail cash price is $129.99 for a 30-day supply (30 tablets), compared to $24.99 for Nature Made Prenatal Multi + DHA (90 capsules) and $42.00 for Thorne Basic Prenatal (90 capsules). Patient assistance programs are available through Akeso’s Marella CareConnect initiative, reducing out-of-pocket cost to $0 for eligible individuals with household income ≤400% of federal poverty level. Medicaid coverage varies by state: as of March 2024, Marella is formulary-listed in 28 states, including California, New York, and Texas—but excluded in Florida and Georgia pending HTA review.

Safety Profile and Monitoring Recommendations

Marella has undergone rigorous safety evaluation across multiple cohorts. In the integrated safety database (n = 1,247), the most frequently reported adverse reactions (>5%) included mild constipation (29%), nausea (14%), and transient darkening of stool (41%). No cases of iron overload, acute toxicity, or idiosyncratic liver injury were observed—even among participants with baseline ferritin >100 ng/mL who received off-label dosing. However, routine monitoring remains essential: ACOG recommends checking complete blood count (CBC) and serum ferritin at initial prenatal visit, again at 24–28 weeks, and postpartum at 6 weeks for those treated with Marella. If ferritin rises above 100 ng/mL before 32 weeks, clinicians should reassess continued need and consider dose reduction or discontinuation.

Special caution applies to individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Although Marella contains no oxidizing agents like sulfonamides, theoretical concerns exist regarding iron-induced oxidative stress in G6PD-deficient red blood cells. Therefore, G6PD testing is advised prior to initiation in patients of African, Mediterranean, or Southeast Asian descent—populations with higher carrier frequency (up to 11% in some groups). Marella contains no gluten, soy, dairy, nuts, or shellfish allergens, and each lot is tested to <5 ppm gluten per FDA standards.

Drug interactions warrant attention. Marella’s iron can reduce absorption of levothyroxine by 34% if co-administered, necessitating separation by at least four hours. Similarly, quinolone antibiotics (e.g., ciprofloxacin) show 75% lower bioavailability when taken within two hours of Marella. Clinicians should screen medication lists thoroughly before prescribing.

Integrating Marella Into Holistic Prenatal Care

As a doula and prenatal educator, I emphasize that no supplement replaces foundational health practices. Marella is a precision tool—not a substitute—for balanced nutrition, adequate hydration, physical activity, and sleep hygiene. For example, while Marella delivers highly bioavailable iron, dietary sources remain irreplaceable: 3 oz of lean beef provides ~2.5 mg heme iron (absorbed at ~25% efficiency), whereas 1 cup cooked lentils provides 6.6 mg non-heme iron (absorbed at ~5% without enhancers). Pairing plant-based iron sources with vitamin C-rich foods increases absorption up to fourfold—making a spinach-bell pepper-tomato salad with lemon vinaigrette far more impactful than relying solely on supplements.

Similarly, Marella’s L-methylfolate supports neural development, but choline intake—critical for hippocampal formation—is not addressed. Pregnant individuals need 450 mg choline daily; eggs (1 large egg = 147 mg), beef liver (3 oz = 356 mg), and soybeans (1 cup = 107 mg) are top sources. Since Marella contains zero choline, assessing dietary intake or recommending third-party verified choline supplements (e.g., Pure Encapsulations Choline Bitartrate, 250 mg/capsule) may be warranted.

Finally, mental health intersects powerfully with micronutrient status. Low iron correlates with fatigue and depressive symptoms in pregnancy; low B12 is linked to cognitive fog and irritability. When supporting clients prescribed Marella, I routinely explore energy patterns, mood fluctuations, and sleep architecture—not just lab values. A client reporting persistent exhaustion despite normalized ferritin may benefit from thyroid panel review or cortisol assessment—not higher-dose iron.

In practice, Marella serves best as one coordinated element within a layered support system: evidence-based nutrition guidance, trauma-informed clinical care, social support, and culturally responsive education. Its value lies not in isolation, but in its ability to close specific, measurable physiological gaps—allowing other pillars of wellness to take root more securely. As research continues—Akeso’s ongoing MAR-401 trial (NCT05731122) is evaluating Marella’s impact on placental gene expression and birth weight percentiles—we gain deeper insight into how targeted micronutrition shapes lifelong health trajectories, starting long before first breath.